Physician profile
Edwin O Byrd
NPI 1891775516
$4,994.88
in general payments reported to CMS, 2019-2025
33 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $945 · 2021: $1,138 · 2022: $952 · 2023: $412 · 2024: $352 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,132 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.68 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $503.91 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $474.33 | 2020-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $473.17 | 2019-2025 | Airsupra |
| Ironshore Pharmaceuticals INC. | $401.26 | 2019-2022 | |
| Pfizer INC. | $353.39 | 2019-2024 | |
| Lilly USA, LLC | $337.10 | 2020-2024 | Zepbound |
| Sanofi-Aventis U.S. LLC | $289.75 | 2020-2022 | |
| Abbvie INC. | $249.76 | 2021-2024 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $244.08 | 2020-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $192.52 | 2021-2022 | |
| Mannkind Corporation | $184.27 | 2021-2023 | Afrezza |
| Exact Sciences Corporation | $159.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $147.90 | 2025 | Zoryve |
| Tris Pharma INC | $130.86 | 2020-2024 | Dyanavel Xr |
| Corium, LLC | $109.25 | 2022-2024 | Azstarys |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $84.40 | 2020-2021 | |
| Allergan, INC. | $83.86 | 2020 | |
| Phathom Pharmaceuticals, INC. | $66.76 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $61.08 | 2019-2024 | Bexsero |
| Inari Medical, INC. | $54.43 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $51.70 | 2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.77 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $40.85 | 2021-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Sanofi Pasteur INC. | $38.51 | 2019-2022 | |
| Abbott Laboratories | $36.14 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $33.87 | 2021 | |
| Collegium Pharmaceutical, INC. | $31.36 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $23.85 | 2019-2020 | |
| Cranial Technologies, INC | $21.84 | 2025 | Doc Band |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.14 | 2022 | |
| Medtronic, INC. | $20.18 | 2021 | |
| Azurity Pharmaceuticals, INC. | $17.82 | 2024 | |
| Daiichi Sankyo INC. | $14.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.